AD-Px
Prognostic engine
Company describes a multimodal prognostic platform whose AD-Px engine forecasts Alzheimer's disease progression to support clinical-research patient selection.
Learn morePerceiv AI
AIDigital Health & HealthTechMontréal, QC
Montréal company, spun out of Mila, whose AD-Px engine uses machine learning to forecast Alzheimer's disease progression for clinical-trial patient selection, and which also sells Foresight care-coordination software to clinics.
Canadian innovation builds a brighter tomorrow.
About
Company site: perceiv.aiMontréal company, spun out of Mila, whose AD-Px engine uses machine learning to forecast Alzheimer's disease progression for clinical-trial patient selection, and which also sells Foresight care-coordination software to clinics.
Québec corporation Recherche Perceiv inc. (Perceiv Research Inc.), NEQ 1173414740, incorporated 2018 in Montréal, status Active. ised-isde.canada.ca
TheraVac Biologics chose Perceiv's AD-Px digital prognostic biomarker engine in January 2025 to optimise patient selection for its TV-301 Alzheimer's trial. newswire.com
Won the 2024 ADRIQ RSRI Innovation Award, with CQDM and DalCor, for an AI project predicting recurrence of cardiovascular events. cqdm.org
Announced a $1.5M investment in December 2022 from CABHI, Plug and Play Ventures, Boreal Ventures, Investissement Québec and others to expand its Foresight platform. prnewswire.com
Products & Services
Company site: perceiv.aiProducts Perceiv AI publishes on its own site. Each card links to the page it was taken from.
Funding & Investors
Announced rounds only, newest first. Undisclosed amounts are shown as undisclosed.
Strategic and institutional investment
Dec 8, 2022
Undisclosedprnewswire.comInvestors: CABHI, Plug and Play Ventures, Boreal Ventures, IKJ Capital, Red Abbey Labs, Investissement Québec
Latest: Strategic and institutional investment · Dec 8, 2022
Partnerships
Publicly announced partnerships.
TheraVac Biologics
Uses Perceiv's AD-Px prognostic engine to optimise patient selection in its TV-301 Alzheimer's clinical trial (January 2025).
Recent News
- Jan 13, 2025Partnership
TheraVac Biologics partners with Perceiv AI to optimize clinical trial
TheraVac Biologics selected Perceiv AI's AD-Px digital prognostic biomarker engine to optimise patient selection for its TV-301 Alzheimer's disease trial.
- Nov 22, 2024Research
CQDM congratulates Perceiv AI, DalCor Pharmaceuticals and Dr. Tardif for winning the 2024 ADRIQ RSRI Innovation Award
A CQDM-supported project by Perceiv AI and DalCor to predict recurrence of cardiovascular events won the 2024 ADRIQ RSRI Innovation Award.
People
Sourced from the company's own pages or announcements.
Christian Dansereau
Founder and Chief Executive Officer
César Laurent
Founder and Chief Technology Officer
Technology Focus
Company site: perceiv.aiTerms the company uses about its own work.
Multimodal prognostic platformAD-Px prognostic engineDigital prognostic biomarker
Similar Companies
Other companies in AI.
